Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy

ConditionsProstate Cancer (Diagnosis)Prostate Cancer Patients Who Have Brachytherapy Seed Implant Prostate Cancer Patients Treated by Radiotherapy Prostate Cancer Recurrent

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexMale

Age18+

SponsorUniversity of Erlangen-Nürnberg Medical School

About this trial

Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.

Eligibility criteria

Qualifiers

Primary treatment with I-125 seeds or HDR-BT

No previous treatment for prostate cancer

Age ≥ 18 years

HDR- or PDR-BT

Disqualifiers

Pre-existent auto-immune disease

patients under bloodthinning medication

substance abuse

Trial design

Treatments tested in this trial

Not listed

Trial groups

200 Participants

are grouped into 2 trial groups

Locations

Klinik für Strahlentherapie86156, AugsburgBavaria, Germany

Strahlenklinik Erlangen91054, ErlangenBavaria, Germany

Klinik und Poliklinik für Strahlentherapie und Radioonkologie81377, MunichBavaria, Germany

Sponsors and collaborators

University of Erlangen-Nürnberg Medical School

Lead sponsor

Bavarian Cancer Research Center (BZKF)

Collaborator

University Hospital Augsburg

Collaborator

Ludwig-Maximilians - University of Munich

Collaborator

Source ClinicalTrials.gov